American Society of Cataract and Refractive Surgery Meeting

American Society of Cataract and Refractive Surgery Meeting

Source:

Gallardo MJ, et al. Ab-interno canaloplasty and trabeculotomy in pseudophakic eyes with mild-moderate open angle glaucoma: Prospective multicenter trial (ORION). Presented at: American Society of Cataract and Refractive Surgery meeting; July 23-27, 2021; Las Vegas.

Disclosures: Flowers reports he is a consultant and investigator for Glaukos and Sight Sciences.
July 27, 2021
1 min read
Save

Omni surgical system reduces IOP, medication use

Source:

Gallardo MJ, et al. Ab-interno canaloplasty and trabeculotomy in pseudophakic eyes with mild-moderate open angle glaucoma: Prospective multicenter trial (ORION). Presented at: American Society of Cataract and Refractive Surgery meeting; July 23-27, 2021; Las Vegas.

Disclosures: Flowers reports he is a consultant and investigator for Glaukos and Sight Sciences.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LAS VEGAS — The Omni surgical system reduced IOP through 3 months in patients with open-angle glaucoma, according to research presented at the American Society of Cataract and Refractive Surgery meeting.

Brian Flowers, MD, presented 3-month interim data from the ORION study exploring the efficacy and safety of the Omni surgical system (Sight Sciences) in pseudophakic eyes with mild to moderate open-angle glaucoma. Patients did not have a history of glaucoma surgery except for implantation of iStent or iStent inject (Glaukos).

In a multicenter study comprising 54 pseudophakic eyes, investigators performed ab interno catheterization and viscodilation of Schlemm’s canal up to 360° followed by trabeculotomy up to 360° using the Omni system.

Patients underwent medication washout and diurnal IOP measurement at baseline and were followed for 12 months. Mean IOP was 17.6 mm Hg at baseline and 26.8 mm Hg after washout.

Brian Flowers

At 3 months, Flowers and colleagues found that 87% off eyes were on no medications with a decrease in IOP of at least 20% to no more than 18 mm Hg. The mean reduction in IOP from baseline among eyes on no medication was 10.3 mm Hg.

The mean number of medications also declined, from 2 at screening to 0.9 at 1 month and 3 months. The mean reduction in medications at 3 months was 1.2.

Common adverse events included layered hyphema in 5.6% and IOP spike, corneal edema and clinically significant macular edema, each in 1.9%.

“It’s interesting that this could be used with ‘failed’ iStent — 28% of eyes had iStents,” Flowers said. “It’s a reasonable procedure to consider in pseudophakic eyes to help you achieve meaningful IOP reduction and medication reduction.”